Moreover, disrupting gal-3 genetically and inhibiting its levels pharmacologically mitigated cardiac fibrosis, left ventricular dysfunction, and ensuing heart failure in murine models (Yu et al., 2013). This evidence concerns the gene LGALS3 and heart failure.